- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502914
The Study on Bacterial Load Following Open-to-air Management in Burn Patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Burns are one of the common forms of trauma and are a cause of unintentional death and injury in the world as well as in the United States (US). Management of burns becomes complex due to multiple associated complications, which result in short-term and long-term disability. Secondary infection of burn wounds is the most common complication associated with burn injuries. Approximately 10,000 people die in the US due to burn-related infections. For instance, gram-negative Pseudomonas aeruginosa is an opportunistic organism commonly found in burn wounds. Bacterial infections cause prolonged hospital stay, increase morbidity, and mortality of burn patients. Treatment of bacterial infections with antibiotics is becoming more challenging due to the development of multidrug-resistance. Hence, current antibiotic regimens and wound care are not always successful in eliminating bacterial infections. As such, there is a critical need to investigate and establish non-antibiotic approaches to prevent colonization, control growth, and eliminate bacteria from burn wounds.
Recent studies have explored the beneficial effects of open-to-air strategies on wound healing, especially in the presence of necrotizing infections. In an open-to air strategy, the wound is left open to the external environment with a heat lamp placed at 6 feet to promote drying. However, the spritz of a topical solution will be applied to avoid excessive drying. Based on current evidence, the investigators hypothesize that bacterial load in burn wounds will be lowered when treated with an open-to-air strategy compared to the traditional closed wound approach.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79430
- Texas Tech University Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 89
- Burn patients with TBSA≥ 20%
- Any suspicion of skin colonization or infection based on a positive result of microbiologic testing. Testing would only be performed if the attending surgeon treating the patient had a clinical suspicion of wound infection.
Exclusion Criteria:
1. Children
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: The experimental group
The experimental group will consist of wounds treated with the open-to-air strategy.
|
In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment.
An electric heat lamp (model no.
53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying.
However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
|
|
Other: The control group
The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
|
In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The bacterial load at baseline for each treatment
Time Frame: At baseline
|
Scrapings of the superficial wound exudate and debris will be obtained at baseline (i.e., the 0-time point before implementing any the tested wound care management option) from both wound sites of each patient. The colony-forming units (CFUs) will be enumerated and CFUs/g will be calculated for treatment and control. |
At baseline
|
|
The bacterial load on day 1 for each treatment
Time Frame: On day 1
|
Scrapings of the superficial wound exudate and debris will be obtained on day 1 (about 24 hours after obtaining samples for baseline measurement) from both wound sites of each patient. The colony-forming units (CFUs) will be enumerated and CFUs/g will be calculated for treatment and control. |
On day 1
|
|
The bacterial load on day 2 for each treatment
Time Frame: On day 2
|
Scrapings of the superficial wound exudate and debris will be obtained on day 2 (about 48 hours after obtaining samples for baseline measurement) from both wound sites of each patient. The colony-forming units (CFUs) will be enumerated and CFUs/g will be calculated for treatment and control. |
On day 2
|
|
Difference in change in bacterial load for day 1
Time Frame: Change in bacterial load from baseline and day 1
|
Change in bacterial load from baseline and day 1 and compared between treatment and control groups.
|
Change in bacterial load from baseline and day 1
|
|
Difference in change in bacterial load for day 2
Time Frame: Change in bacterial load from baseline and day 2
|
Change in bacterial load from baseline and day 2 and compared between treatment and control groups.
|
Change in bacterial load from baseline and day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of bacterial species at baseline for each treatment
Time Frame: At baseline
|
Scrapings of the superficial wound exudate and debris will be obtained at baseline from both wound sites of each patient. Debridement samples will be homogenized and serially diluted.The dilutions will be spot plated on selective agar. |
At baseline
|
|
Prevalence of bacterial species on day 1 for each treatment
Time Frame: On day 1
|
Scrapings of the superficial wound exudate and debris will be obtained at baseline on day 1 from both wound sites of each patient. Debridement samples will be homogenized and serially diluted.The dilutions will be spot plated on selective agar. |
On day 1
|
|
Prevalence of bacterial species on day 1 for each treatment
Time Frame: On day 2
|
Scrapings of the superficial wound exudate and debris will be obtained on day 2 from both wound sites of each patient. Debridement samples will be homogenized and serially diluted.The dilutions will be spot plated on selective agar. |
On day 2
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Yang D, Davies A, Burge B, Watkins P, Dissanaike S. Open-to-Air Is a Viable Option for Initial Wound Care in Necrotizing Soft Tissue Infection that Allows Early Detection of Recurrence without Need for Painful Dressing Changes or Return to Operating Room. Surg Infect (Larchmt). 2018 Jan;19(1):65-70. doi: 10.1089/sur.2017.080. Epub 2017 Dec 6.
- Dai T, Gupta A, Huang YY, Yin R, Murray CK, Vrahas MS, Sherwood ME, Tegos GP, Hamblin MR. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother. 2013 Mar;57(3):1238-45. doi: 10.1128/AAC.01652-12. Epub 2012 Dec 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB #: L20-067
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
Sun Yat-sen UniversityCompleted
-
Hennepin Healthcare Research InstituteNot yet recruiting
-
Buckinghamshire Healthcare NHS TrustNot yet recruitingBurns Multiple
-
Virginia Commonwealth UniversityNot yet recruiting
-
Riphah International UniversityActive, not recruiting
Clinical Trials on Open-to-air strategy
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedRespiratory Insufficiency | Postoperative Pulmonary ComplicationsChina
-
University Hospital, MontpellierRecruiting
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Fraunhofer-Institute of Toxicology and Experimental...CompletedHealthy | Chronic Obstructive Pulmonary DiseaseGermany
-
University of California, DavisCompletedScreening for Colon CancerUnited States
-
Villanova UniversityCompletedAir Pollution, Risk Reduction BehaviorsUnited States
-
M.D. Anderson Cancer CenterActive, not recruiting
-
Ankara Etlik City HospitalRecruitingFibromyalgiaTurkey (Türkiye)
-
National Health Service, United KingdomUnknownLaser | Capillary Malformation | Skin CoolingUnited Kingdom
-
Florida International UniversityThe University of Texas Health Science Center, Houston; National Heart, Lung... and other collaboratorsNot yet recruiting